x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230951
| Product Information | |
|---|---|
| CAS No. | 2735803-28-6 |
| Formula | C18H20O3 |
| Molecular Weight | 284.35 |
| Target | ERRα |
| Product Description | DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM). |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Protect from light. Powder: -80 °C, 2 years; -20 °C, 1 year. In solvent: -80 °C, 6 months; -20 °C, 1 month (protect from light). |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
